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Abstract
Genome-wide association studies (GWAS) for type 1 diabetes (T1D) have successfully identified more than 40 independent
T1D associated tagging single nucleotide polymorphisms (SNPs). However, owing to technical limitations of copy number
variants (CNVs) genotyping assays, the assessment of the role of CNVs has been limited to the subset of these in high
linkage disequilibrium with tag SNPs. The contribution of untagged CNVs, often multi-allelic and difficult to genotype using
existing assays, to the heritability of T1D remains an open question. To investigate this issue, we designed a custom
comparative genetic hybridization array (aCGH) specifically designed to assay untagged CNV loci identified from a variety of
sources. To overcome the technical limitations of the case control design for this class of CNVs, we genotyped the Type 1
Diabetes Genetics Consortium (T1DGC) family resource (representing 3,903 transmissions from parents to affected
offspring) and used an association testing strategy that does not necessitate obtaining discrete genotypes. Our design
targeted 4,309 CNVs, of which 3,410 passed stringent quality control filters. As a positive control, the scan confirmed the
known T1D association at the INS locus by direct typing of the 59 variable number of tandem repeat (VNTR) locus. Our
results clarify the fact that the disease association is indistinguishable from the two main polymorphic allele classes of the
INS VNTR, class I-and class III. We also identified novel technical artifacts resulting into spurious associations at the
somatically rearranging loci, T cell receptor, TCRA/TCRD and TCRB, and Immunoglobulin heavy chain, IGH, loci on
chromosomes 14q11.2, 7q34 and 14q32.33, respectively. However, our data did not identify novel T1D loci. Our results do
not support a major role of untagged CNVs in T1D heritability.
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Introduction
Type 1 diabetes (T1D) is a complex common autoimmune
disorder that is diagnosed in approximately 1 in 350 children in
the UK [1,2]. Its etiology arises from the action of multiple
genetic and environmental risk factors [3,4], with nearly one-
half of the genetic risk residing in the human HLA-Major
Histocompatibility Complex (MHC). In addition to the MHC,
genome-wide association studies (GWAS) have identified over
40 loci robustly associated loci ([5,6] and www.t1dbase.org). As
for most complex human traits, T1D heritability and the extent
of this heritability that remains to be discovered, are topics of
debate [7]. While the gap between what is explained by known
loci and true heritability is likely to be relatively small compared
to other complex disorders [8], it is clear that additional
variants remain to be found, with the potential to bring novel
insights into T1D etiology. However, discovery of these variants
will require either a significant sample size increase from
previous well-powered GWASes [5], or alternative strategies
that can target variants not captured by the standard GWAS
design.
GWAS studies rely on a tag single nucleotide polymorphisms
(SNPs) strategy to capture the extent of variation of the human
genome and identify association signals. Variants poorly tagged by
GWAS tag SNPs are therefore of primary interest for association
purposes. Putative rare variants with high effect sizes fall into this
category [9,10]. Another class of variation that can be poorly
tagged by the GWAS design are copy number variants (CNVs).
The pathogenic potential of CNVs is supported by their larger
sizes, and therefore their increased likelihood to perturb molecular
mechanisms. CNVs have been implicated in the etiology of several
diseases, in particular developmental disorders [11]. The effec-
tiveness of GWAS SNPs to tag CNVs depends on the type of
CNVs being assayed. Biallelic CNVs generally result from a single
ancestral mutation and their tagging properties closely match
those of SNPs [12–14]. In contrast, highly polymorphic multi-
allelic CNVs may mutate frequently enough to be in low linkage
disequilibrium (LD) with GWAS tag SNPs.
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These observations indicate that untagged CNVs could play a
significant role in the etiology of complex traits. This hypothesis is
further warranted by previous reports of associations between
difficult to genotype multi-allelic CNVs and HIV risk [15], as well
as systemic lupus erythematosus [16]. T1D is a particularly
relevant disease to assess the role of multi-allelic CNVs, owing to
the established association of a variable number tandem repeat
(VNTR) locus near the INS gene. While the INS locus can be used
as a positive control for T1D, it is however not yet known whether
the INS VNTR itself, or another nearby genetic variant, is actually
causal [17].
Owing to our aim to assess the role of untagged CNVs, a
genome-wide CNV scan needs to directly target these variants.
This requirement has limited the ability to thoroughly investigate
the role of CNVs for most complex traits, in particular T1D. The
Wellcome Trust Case Control Consortium (WTCCC) has
performed a recent large scale CNV association study using a
custom designed array comparative genomic hybridization
(aCGH) in a collection of 16,000 cases of eight common diseases,
including T1D, and 3,000 shared controls [18]. In this effort, over
3,400 polymorphic CNVs were evaluated. While this study did not
identify novel T1D associations, its coverage was limited by the
relative inefficacy of the case control association to test CNVs for
association. The primary reason for this limitation is that, in
situations where one cannot assign discrete copy number classes to
individuals at a given (‘unclusterable’) locus, subtle technical
differences between cases and controls affect the CNV intensity
data in a manner that inflates the false positive rate [19,20].
Unclusterable CNVs were therefore not included in the final
WTCCC CNV analysis [18], which highlights the challenge
associated with assessing this class of variants. To overcome these
technical limitations, we must use an alternative to the case control
strategy, which motivated the use of a family design. Accordingly,
novel methodologies have been developed for family based
association tests that do not rely on discrete CNV genotypes but
can directly incorporate raw CNV intensity data [21,22].
To test the hypothesis that unclusterable CNVs contribute to
T1D heritability, we used the collection of T1D multiplexed
families recruited by the T1D Genetics Consortium (T1DGC).
These samples add up to more than 4,000 transmissions between
parents and affected offspring. We designed an aCGH that builds
upon previous CNV discovery and genotyping experiments
[12,18,23] but whose targets are enriched for previously untagged
CNVs, for which discrete calls typically cannot be obtained. We
then used this custom array to genotype the T1DGC samples and
perform a genome-wide scan for T1D association.
Results
Array design and CNV based quality control
CNVs targeted by our CGH array (Methods) were gathered
from a combination of published studies of CNVs in the general
population based on both CGH [12,18] and short read genome-
wide sequence data [23,24]. Combining all sources, we targeted
4,309 CNVs (Figure 1 and Tables S1-2) that were deliberately
enriched for untagged (r2,0.6 with best GWAS tag, Methods) and
difficult to genotype loci. We were able to design probes for 4,207
loci, with the excluded loci typically being highly repeated regions
in multiple genomic locations. We applied multiple QC steps to
remove CNVs affected by technical artifacts (Methods). 3,410
CNV loci passed these filters. Of these, 848 CNVs were
clusterable, in the sense that the intensity data could be clustered
into distinct groups by the CNVtools software [19]. Table S2 lists
the type of CNVs targeted by the aCGH, before and after
applying QC filters. 35.9% of these 3,410 CNV loci overlap a
protein coding gene (intron or exon) and 16.42% overlap a coding
sequence of these genes. The median CNV size if 5.34 kb (5%
quantile: 0.17 kb and 95% quantile: 64.156 kb).
Genotyping quality and sample based quality control
Combining the four cohorts that constitute the T1DGC
collection, a total of 8,460 samples were sent for genotyping
(Table 1). We ensured that within each family, the same primary
source of DNA (e.g. blood, cell-line) was used for every family
member to minimise technical biases within families. These
samples add up to 3,856 transmissions from parents to affected
offspring. Following QC exclusions, 8,005 samples/3,630 trans-
missions were usable for the case control association tests. In
addition, Illumina ImmunoChip genotype data were also available
for all samples. The most common exclusion criteria were quality
below the metrics suggested by Agilent QC, and non-concordance
with the ImmunoChip dataset, potentially indicative of sample
swaps.
Association testing strategy
Our association test strategy uses the previously developed
CNV-family based association test (FBAT-CNV [22]), which is
based on raw CNV intensity data rather than discrete calls. The
key motivation for FBAT-CNV is to avoid the spurious false
positive associations caused by technical differences between
cases and controls. Instead, tests are performed within family
units, comparing CNV data between affected offspring and
parental average. This test does not require the CNV intensity
data to be clearly separated into discrete classes (i.e. ‘‘cluster-
able’’), in contrast with case-control association tests. Figure 2
schematically describes the differences between case-control and
FBAT-CNV.
Prior to applying the FBAT-CNV test, different strategies can
be used to normalize the CNV probe data, as well as summarize
the intensity data from multiple probes at a single CNV locus.
Overall we considered 12 different strategies, including a
heritability variance scaling (HVS) scheme that builds on the
Author Summary
For many complex traits, and in particular type 1 diabetes
(T1D), the genome-wide association study (GWAS) design
has been successful at detecting a large number of loci
that contribute disease risk. However, in the case of T1D as
well as almost all other traits, the sum of these loci does
not fully explain the heritability estimated from familial
studies. This observation raises the possibility that addi-
tional variants exist but have not yet been found because
they have not effectively been targeted by the GWAS
design. Here, we focus on a specific class of large
deletions/duplications called copy number variants (CNVs),
and more precisely to the subset of these loci that mutate
rapidly, which are highly polymorphic. A consequence of
this high level of polymorphism is that these variants have
typically not been captured by previous GWAS studies. We
use a family based design that is optimized to capture
these previously untested variants. We then perform a
genome-wide scan to assess their contribution to T1D. Our
scan was technically successful but did not identify novel
associations. This suggests that little was missed by the
GWAS strategy, and that the remaining heritability of T1D
is most likely driven by a large number of variants, either
rare of common, but with a small individual contribution
to disease risk.
A Genome-Wide Assessment of Untagged CNVs in T1D
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probe variance scaling idea proposed in [18]. HVS maximizes the
weights of probes with more heritable CNV signal (Methods). Our
final pipeline selected for each CNV the optimum strategy, as
measured by within family correlations (Figure S1). The rationale
for this choice being that probes with heritable signals are more
likely to capture true heritable CNV differences, and less likely to
be affected by noise.
Power of FBAT-CNV test
Previous investigations of the properties of the FBAT-CNV test
focused on demonstrating its validity, i.e. consistency of P-value
distribution under the null with theoretical expectations [21,22].
Assessing the power of the FBAT-CNV test using theoretical
arguments is likely to be assay dependent. To empirically address
the issue of power, we used the subset of 22 clusterable CNVs
located in the HLA- MHC chromosome region, known to be T1D
associated. For these CNVs a linear standard TDT based on
discrete genotypes should provide a near-optimum association
testing strategy.
Figure S2 compares these TDT P-values with the result of the
FBAT-CNV test. The significance of these association P-values
was broadly equivalent for both testing strategies. This result
suggests that, at least in the context of this study, the FBAT-CNV
retains appropriate power for association testing. Unless stated
otherwise, we based analyses on the FBAT-CNV association tests,
independently of whether discrete genotypes were available. Table
S3 lists all targeted CNVs and positions with the associated FBAT
P-values.
The comparable statistical power between FBAT-CNV and
TDT provides the opportunity to use established TDT power study
methodology [25] to determine the range of CNVs for which our
study is well powered. At a P-value threshold of P,1026 a TDT
with 3,610 transmissions to affected offsprings provides 80% power
for bi-allelic CNVs with frequency 40% and odds ratio 1.22.
Figure 1. Summary of the CNVs included in the array design and tested for T1D association using FBAT-CNV. CNVs originate from two
main sources: the GSV map of common CNVs [27] and the 1,000 Genomes sequence data. Tested CNVs also include 365 novel insertion CNVs
obtained from the Venter genome. Detailed description of the array design is provided in Text S1.
doi:10.1371/journal.pgen.1004367.g001
Table 1. Number of transmissions between parents and affected T1D offspring, before/after applying QC steps.
QC step Blood LCL Total Percentage
Before QC 3244 612 3856 100
Agilent standard QC metrics 3075 555 3630 94.14
Consistency of familial relationships 3016 551 3567 92.51
Sample correlation 3072 555 3627 94.06
Gender check 3047 553 3600 93.36
Sample tracking 3020 555 3575 92.71
Heterozygosity 3075 555 3630 94.14
After QC 3075 555 3630 94.14
doi:10.1371/journal.pgen.1004367.t001
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Spurious associations at the TCR and IGH loci
We observed strong evidence of T1D association (P,10210) at
two loci that had been previously identified as affected by
somatic rearrangements in haematopoietic lineages:
CNVR6085.1, which overlaps the TCR alpha/delta (TCRA/
TCRD) chain locus on chr14q11.2, and CNVR3590.1, which
overlaps the TCR beta (TCRB) chain on chr7q34. Strong
difference in probe intensity between DNA extracted from blood
and LCLs at these loci have been previously reported [18] and
our data confirm this (Figures 3A-B). However, FBAT-CNV
association tests are family based and DNA source is homoge-
neous within the T1DGC families, hence this issue is unlikely to
explain these strong associations. However, inspection of the
intensity data showed correlations between age at sampling and
probe intensity at both loci for DNA extracted from blood
samples (Figures 3A-B). This trend is also observed in offspring
after exclusion of parental intensity data. This observation
suggests that the different average signal in offspring compared to
parents is not a consequence of their T1D affected status, but
rather of the differential age when blood was collected. We
hypothesize that this trend is caused by age-dependent variability
in cell type frequencies with different somatic mutation profiles.
Combined with the inevitable younger age of offspring, it likely
explains the strong signal of association.
In addition, moderate evidence of association (P= 6.561025)
was found at the IgG locus on chromosome 14q32.33
(CNVR6294.22, as well as several other CNVs in high LD with
CNVR6294.22). We also observed at this locus a strong LCL/
blood difference (Figure 3C). However, as pointed out above, tests
are performed within-family and therefore this LCL-blood
difference is unlikely to explain this association signal. Unlike the
TCR loci, no age dependent effect was detected (Figure 3C),
which leaves no explanation for this association. Nevertheless, the
technical issues associated with this somatically variable locus
strongly suggest that this association is the result of an unidentified
technical artifact.
Figure 2. Differences between case-control and FBAT-CNV association tests. A- In a case-control analysis, technical variability may affect
the CNV intensity data between cases and controls. Therefore, it is necessary to call the discrete genotypes, potentially allowing for genotype
uncertainty in the association tests. Mixture models are typically used for calling, as illustrated by the colored lines on top of the histograms. Intensity
data must therefore be sufficiently separated to make these discrete calls (CNV data in this example obtained from both control groups in the WTCCC
study [28]). B- With the FBAT-CNV framework, one compares the average parental CNV signal with the signal for affected offspring. Consistent
deviation of affected offspring intensity data compared to parental average indicates biased transmission of CNV alleles. As the test is solely based on
the intensity data, and no systematic bias is expected between parents and offspring, it is not necessary to make discrete calls (CNV data obtained
from INS VNTR first principal component).
doi:10.1371/journal.pgen.1004367.g002
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Genome-wide distribution of the test statistic for T1D
associations
Owing to our focus on CNVs difficult to genotype, and the
challenge of obtaining interpretable association statistics for these
loci, we initially verified that our association P-values were broadly
consistent with the null hypothesis. Figure 4A shows the
distribution of association statistics for 3,286 post-QC CNVs after
excluding IgG/TCR loci described above. Figure 4B shows the
distribution of the test statistic for the same set of loci after
excluding previously reported associated CNVs (HLA-MHC, INS
and the IgG/TCR loci). These results indicate that while some
over-dispersion remains, its level is limited (over-dispersion slope of
1.23, Figure 4B). In particular, the association test statistic for 447
VNTRs that passed QC showed good concordance with the
expectation under the null (over-dispersion slope 1.103, Figure 4C),
with the exception of the established T1D associated INS VNTR,
which showed unequivocal evidence of T1D association (P,
10250).
Manhattan plot and genome-wide results of the scan
Figure 5 shows the Manhattan plot for the association test
statistic, computed for each CNV locus. In addition to the age
Figure 3. Spurious associations at TCR and IGH loci. Age at sampling (x-axis) versus CNV intensity signal (y-axis) for the three most associated
Immunoglobin Heavy (IGH) and T cell receptor (TCR) loci CNVs. Each point represents an individual in the study (irrespective of familial/T1D status).
Blue crosses indicate DNA extracted from LCLs (N= 551) and red crosses DNA extracted from blood (N= 2,981). Red and blue lines have been fitted to
the LCL/blood data using cubic splines. A - CNVR6085.1 (chr14:21977832-21987926) mapping to TCR alpha and TCR delta locus on chr14, FBAT-CNV
P= 3.6 10263. The plot shows correlation between age at sampling and probe intensity for DNA extracted from blood samples. B - CNVR3590.1
(chr7:142194021-142204412) mapping to TCR beta locus on chr7, FBAT-CNV P=4.4 10231. The plot shows correlation between age at sampling and
probe intensity for DNA extracted from blood samples. C - CNVR6294.22 (chr14:105433837-105441555) mapping to Ig heavy chain locus on chr14,
FBAT-CNV P=6.5 1025. No age-dependent effect was detected at this locus.
doi:10.1371/journal.pgen.1004367.g003
Figure 4. Quantile-quantile plot comparing the expected versus the observed distribution of the FBAT-CNV P-values. These plots
show the distribution of -2log10(p), which is, under the null, distributed as chi-square with 2 degrees-of-freedom. IgG/TCR loci are discussed
elsewhere and not included in these plots. A – N= 3,286 CNVs that passed quality controls and were tested for association. Loci overlapping the MHC
region are marked in blue. Loci mapping to, or in strong LD with, the INS VNTR region are marked in red. B – N= 3,214 CNVs passed quality controls
and did not overlap or tagged the INS VNTR and the MHC region. C – N= 448 VNTRs targeted by the CGH array that passed quality controls. INS VNTR
CNV regions are marked in red as in Figure 3A.
doi:10.1371/journal.pgen.1004367.g004
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related effects observed at the IGH and TCR loci, two previously
associated loci showed strong association results: multiple CNVs in
the MHC-HLA region, as well as a smaller set of CNVs either
directly targeting of located near the INS VNTR sequence (see
below). We also identified a strong signal of association on
chromosome 2q31, which has been previously identified as a
duplication of this region into the HLA-MHC region, which
accounts for the observed association signal.
In addition to these previously reported associations, a set of
CNV loci in high LD, located in 1q21 (near the centromeric
region of chromosome 1), passed the P= 0.05 Bonferroni
correction threshold for 3,410 loci (corrected threshold P,
1.4661025). The most associated CNV is an unclusterable
duplication (CNVR341.1, Table 2, P= 3.3961026), which over-
laps the first three exons of the gene NOTCH2NL. After excluding
known loci (MHC-HLA, INS, TCRA/TCRD, IGH), five out of the
ten most associated CNVs are located in the same 1q21 region
(Table 2), hence excluding the possibility of a technical artifact that
would affect a single CNV.
Follow-up testing for the CNVs in the 1q21 region
The suggestive evidence of T1D association in 1q21 prompted
us to attempt replication for this potential finding. While the top
CNV region CNVR341.1 is unclusterable, CNVR334.3 in the
same genomic region is clusterable and also shows a similar
strength of association (FBAT P-value 5.861024, Table S2). Case
control data from the WTCCC+ was of sufficient quality for case
control association testing using the CNVtools [19] software. We
found no significant association (P= 0.24) in these samples (2,000
cases, 3,000 controls, Figure S3). We hypothesized that the lack of
replication could be a result of a weak effect combined with the
limited power provided by the case control cohort. The previous
WTCCC+ analysis indicates that rs4649771 is a good quality SNP
tag for CNVR334.3. Therefore, we used a tag SNP strategy and
typed this SNP (Methods) in the full JDRF/Wellcome Trust
Diabetes and Inflammation Laboratory case control collection
(Genetic Resource Investigating Diabetes, 7,814 cases and 9,785
controls, which included the WTCCC+ samples, Methods). We
also found no evidence of T1D association (P= 0.9).
The class I-class III alleles fully account for the INS VNTR
T1D association
To understand the causal mechanism that underlies the INS
gene/T1D association, we tiled aCGH probes across the
representative sequences of all four major alleles of the VNTR
in European populations (Methods). Overall, 100 aCGH tiling
probes targeted the INS VNTR sequence. Additional genotype
data for the nearby SNP rs689 (-23HphI, thought to separate class
I and class III alleles) and rs3842756 (+1428 FokI, thought to
distinguish two subclasses of class III alleles, PH and VPH [17])
were available from the additional T1DGC ImmunoChip
genotyping of the same cohort (Methods).
We decomposed the signal provided by the aCGH probes using
principal component analysis (PCA). We found that PC1-PC2
captures the signal provided by the SNP rs689 (Figure 6), which is
known to distinguish almost perfectly between class I and class III
Figure 5. Manhattan plot for the FBAT-CNV P-values. The y-axis shows the distribution of –log10(p) where p is the FBAT-CNV test association
test P-value for all CNV loci passing quality control filters (Methods). The x-axis shows chromosomes numbered from 1 (left) to X (right).
doi:10.1371/journal.pgen.1004367.g005
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alleles of the VNTR [26].T1D association with rs689 was
convincing (TDT test P= 5.4610252) and consistent with the
FBAT CNV analysis for PC1-PC2 (P = 1610242 for PC1, and
P=161028 for PC2)
To detect potential secondary signals at the VNTR loci from
this main class I-class III effect, we performed conditional tests of
association, excluding the families for which either of the parents
was heterozygous at rs689. rs3842756 showed no evidence of
association (P.0.05, with 1,432 transmissions from parents to
affected offspring remaining). Similarly, a FBAT-CNV test for the
all PCs 1-10 in that subset of individuals showed no evidence of
association (P.0.05 for all, Figure S4). These results indicate that
T1D association signal is driven by either rs689, or the SNP in
strong LD with rs689, rs3842753 (+1140 A/C; r2 = 1), or the
combination of PC1-PC2, both of them tagging the INS VNTR
class I-class III alleles. Our data do not support the presence of a
secondary association within the INS VNTR locus.
Discussion
We performed a well-powered genome-wide scan for previously
untested and untagged CNVs using a family based design. This is
the first successful genome-wide association study for VNTRs and
other multi-allelic CNVs. Our study targeted 3,410 CNVs,
including 448 VNTRs, and a direct assessment of the role of the
INS VNTR in T1D. The limited over-dispersion of the test statistic
and the clear detection of strong association for the INS VNTR
indicate that the family-based strategy we adopted was technically
successful. These results are in stark contrast with previous
genome-wide association using a case-control strategy [18], which
had to exclude from the final analysis those CNVs whose raw
intensity data was not clusterable into discrete genotypes. In
addition to established loci and a small number of technical
artifacts, a single set of CNV associations located in 1q21 passed a
Bonferroni threshold of association. However, the replication
results were negative, suggesting that this result is the consequence
of stochastic variability rather than biologically meaningful signal.
Taken together, and with the caveat that our coverage of CNVs
genome-wide is not exhaustive, our results suggest that this class of
CNVs does not contribute significantly to the heritability of T1D.
The INS VNTR is of particular interest for T1D etiology owing
to its strongest effect size among all non-HLA variants, along side
the PTPN22 nsSNP rs2476601. By directly targeting this VNTR
using a dense set of tiling probes, we can rule out the presence of a
secondary association within the VNTR locus. The primary
association is driven either by the class I-class III allele split
(captured by PC1-PC2 in our PCA analysis of this locus), or by the
rs689 (-23HphI) variant and/or a second SNP, rs3842753, all three
of them indistinguishable, as reported previously [17]. Alternative
strategies will probably be required to answer the question of what
the causal variant(s) and mechanism actually is, as the perfect LD
in population of European ancestry will probably prevent genetic
epidemiological studies in European populations from providing
this answer.
While the distribution of association P-values is sufficiently close
to its expectation under the null to interpret the results of our scan,
Table 2. Top ten T1D associated CNVs after removing known loci and technical artifacts.
CNV Genomic Coordinates Source Type P-value Genes with overlapping exons
CNVR341.1 chr1:143900933-143967112 WTCCC+ unclusterable but real duplication 3.39E-06 NOTCH2NL
CNVR335.2 chr1:143214434-143238273 WTCCC+ unclusterable but real duplication 2.78E-05 -
CNVR4502.1 chr9:134934317-134947466 WTCCC+ untagged duplication 4.23E-05 -
CNVR339.1 chr1:143659640-143795351 WTCCC+ unclusterable but real duplication 4.56E-05 PDE4DIP
CNVR8001.1 chr21:35523151-35524232 WTCCC+ untagged deletion 5.32E-05 -
CNVR6488.1 chr15:82862339-82873960 WTCCC+ unclusterable but real deletion 9.34E-05 -
CNVR349.3 chr1:147052241-147090322 WTCCC+ unclusterable but real duplication 1.91E-04 -
G1KSVR.1_3 chr1:146398811-146416090 G1K untagged deletion 2.78E-04 -
CNVR986.1 chr2:130682838-130684330 WTCCC+ untagged deletion 2.85E-04 -
CNVR8248.1 chrX:1895433-1900059 WTCCC+ unclusterable but real duplication/deletion 2.93E-04 -
The last column lists the genes for which at least one exon overlaps the defined CNV region. P-value refers to the FBAT association test for autosomal CNVs, and to the
FBAT-X association test otherwise.
doi:10.1371/journal.pgen.1004367.t002
Figure 6. Decomposition of multi-probe CNV data at the INS
VNTR locus into first two principal components PC1 and PC2.
Principal components PC1 and PC2 summarize the multi-probe CNV
data at the INS VNTR locus. Colors (green/red/black) were chosen based
on the genotypes of the SNP rs689 (AA/AT/TT), which captures the class
I-class III separation.
doi:10.1371/journal.pgen.1004367.g006
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the level of over-dispersion remains higher than typically reported
in GWAS studies. This may partly reflect artifacts such as the ones
observed at the IGH/TCR loci. In addition, for CNVs with non-
linear intensity-copy number relationship, FBAT-CNV, departure
from Hardy-Weinberg equilibrium (HWE) can inflate the type 1
error [21]. Hence, population structure in the parental samples
leading to departure from HWE could explain the moderately
biased distribution of the FBAT-CNV association statistics.
Here, we have extended the set of genetic variants considered in
T1D association studies to include a major novel category of
CNVs. However, this set is still limited by the requirement to
design short oligonucleotide probes for the aCGH assay that have
minimal matches elsewhere in the genome. Shorter repeats
regions, in particular microsatellites, remain out of reach of
genome-wide association tests using array-based technologies. The
typically higher mutation rate of microsatellites could lead to a
mutation-selection equilibrium that is compatible with larger odds
ratio of association for T1D. Targeting these variants will require
large scale sequencing studies with sufficiently long reads to
characterize these difficult loci reliably. Future improvements of
sequencing technologies will provide an opportunity to further
broaden the scope of association tests in the future.
Materials and Methods
CNV selection
CNVs selected as targets originated from the following sources:
(i) Loci from the WTCCC+ genotyping chip that were classified as
successfully genotyped but at the same time untagged by SNPs in
the WTCCC+ study, (ii) Loci from the GSV/WTCCC+ set that
could not be genotyped but that were classified as real
polymorphisms in the WTCCC+ study, (iii) Loci from the 1000
Genomes project union set of deletions from Pilot 1 (low coverage
samples) and Pilot 2 (high coverage trio samples) phases that were
genotyped but were not tagged by SNPs in the 1000 genomes
project (PhaseI + PhaseII), (iv) Loci from the 1000 Genomes
project union set of deletions from Pilot 1 (low coverage samples)
and Pilot 2 (high coverage trio samples) phases of the 1000
genomes project for which the SNP tagging status was unknown
and lied in T1D association intervals, (v) Insertions of novel
sequences present in the genome sequence of Craig Venter but not
in the reference sequence that were not previously tested for
association in the WTCCC+ study, (vi) candidate gene loci
PRDM9 VNTR and NCF1 gene, (vii) functional elements in T1D
intervals, (viii) Control loci from WTCCC1 X-chromosome CNV
desert regions and from a set of CNV loci genotyped in the
WTCCC+ study or in the 1000 Genomes project to facilitate
detection of sample mishandling. A more detailed breakdown of
the target loci is given in Text S1 and Figures S5-7. Table S4
provides the bed file that was sent to Agilent for array design.
Samples
The Type 1 Diabetes Genetics Consortium (T1DGC) repre-
sented an international effort to identify genes that determine an
individual’s risk of T1D. A major effort of the T1DGC was the
creation of a resource base of well-characterized families from
multiple ethnic groups to facilitate the localization and character-
ization of T1D susceptibility genes. After consideration of previous
genome-wide linkage scan results for T1D, the contributions of
known T1D risk loci to familial clustering of T1D, and the power
of affected sib-pair linkage studies, the T1DGC proposed to
assemble a collection of 4,000 affected sib-pair (ASP) families,
requiring de novo recruitment of,2,800 ASP families. In order to
identify, recruit, and collect the samples and data on these newly
ascertained ASP families, the T1DGC developed four regional
networks: North America (NA), Europe (EU), United Kingdom
(UK), and Asia Pacific (AP). Within each network, field centers
identified, ascertained, and collected samples and data from
participating families, with samples shipped and processed in
laboratories at multiple sites. Each network had a repository to
process samples for DNA and to provide cell immortalization
using standard protocols. Samples and data from the T1DGC
network laboratories have been transferred to the central NIDDK
repository (www.niddkrepository.gov) from which investigators
can make requests.
Protocols and informed consents for sharing of data and samples
were approved by review boards of all contributing institutions,
and appropriate informed consent was obtained from families.
Briefly, a family must contain at least one affected sib-pair;
‘‘affected’’ indicates a diagnosis of T1D in the proband (index case)
before the age of 35 years, with insulin required within 6 months of
diagnosis. Two sources of DNA were available, blood (DNA was
extracted from cell pellet collected during plasma isolation from
blood) and EBV-transformed lymphoblastoid cell lines (LCLs).
Only families with one source of DNA were included (all members
with blood DNA (N=7,152) prioritized over all members with cell
line DNA (N=1,308)). From this filtering, 8,460 individuals were
included for the CNV study, 1,661 families with at least four
members (2 parents and 2 affected children, n= 6,963) and 499
families with three members (2 parents and an affected child,
n = 1,497).
DNA processing
The T1DGC DNA stock plates were thawed to room
temperature, typically for at least three hours to ensure that the
DNA was homogeneous. The stock plates were vortexed at 1000
rpm for 1 minute, then centrifuged at 280 xg for 1 minute. Stock
DNA concentrations were determined using a Nanodrop spectro-
photometer. An 18 ul sample from the DNA stock plate was
transferred to a CNV dilution plate, after which all samples were
normalized using 10 mM Tris either at University of Virginia
(Charlottesville, VA) or the OGT facility (Oxford, UK). Once the
samples were diluted, the plates were vortexed at 1000 rpm for 1
minute and centrifuged at 280 xg for 1 minute. The plates were
allowed to incubate at room temperature for 30 minutes. DNA
concentration of the CNV dilution plates were evaluated using a
Nanodrop spectrophotometer, targeting a range of 60–70 ng/ul
(acceptable was considered 40–80 ng/ul). For samples out of range
(e.g., a sample higher than 80 ng/ul), more Tris buffer was added,
mixed, and reassessed. Once all of the samples were within the
desired concentration range, the CNV dilution plates were sealed
and stored them at 4uC. A Biomek FX robot was used to transfer
15 ul of each sample from the CNV dilution plates to daughter
plates, that were then heat-sealed and stored at 220uC until
shipped to Oxford Gene Technology (OGT, Oxford, England)
and processed.
aCGH data generation
Data were generated using the Agilent 8660k custom array
CGH at the OGT facility (Oxford, UK). Samples were platted in
rows. Families were processed within the sample plates, with
family members in consecutive wells and random permutations to
change the position of the family members on the columns. All
family members were processed on the same custom array slide.
The shared reference DNA sample for the entire study is a pool of
genomic LCL DNA from 10 male HapMap subjects (NA06994,
NA07051, NA11992, NA12003, NA12043, NA12045, NA12144,
NA12155, NA12750, NA12891). Equal amounts of test and
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reference DNA were used in the DNA labeling reactions and
hybridized to the custom array. Following hybridization the arrays
were scanned using the red channel for the test sample and the
green channel for the reference sample. An internal control
reaction was carried out on each plate to assess DNA labeling and
hybridization steps.
Data processing
Prior to data analysis we normalised the data in 6 different ways
by applying some transformations of the red (R) and green (G) raw
copy number intensities as proposed in [18] (QNorm refers to






6. log(QNorm(R)/QNorm(G) + 0.5)
Multiple probes at a single CNV were summarized using a PCA
analysis (without rescaling the probe data to unit variance). In
addition, it has been pointed out before [18] that the contribution
of each probe to the intensity signal is variable. We took advantage
of the family design to increase weight for probes likely to be more
informative, a method we called heritability probe scaling (HPS).
Precisely, for each probe on the array, we estimated correlation
between offspring and mid-parental intensities. HPS then rescales
probe intensities proportionally to this measure of heritability.
Combining these 6 normalizations and 2 different probe
summary techniques (PCA and HPS-PCA), we considered 12
different data summaries per CNV. At each of the 4,201 CNV
loci, we selected the method among these 12 that maximized the
correlations between mid-parental intensity and used this choice in
the association tests (Figure S1).
Case-control dataset of replication
Case subjects were diagnosed with T1D before 17 years of age
(mean age at diagnosis 7.8 years) and were from the Juvenile
Diabetes Research Foundation/Wellcome Trust Diabetes and
Inflammation Laboratory Genetic Resource Investigating Diabe-
tes study (www.childhood-diabetes.org.uk/grid.shtml). Control
subjects were obtained from the British 1958 Birth Cohort
(www.cls.ioe.ac.uk/studies.asp?section = 000100020003) and the
Wellcome Trust Case-Control Consortium U.K. Blood Service
Common Control sample collection. All samples were of white
European ancestry.
Genotyping replication of rs4649771
rs4649771 was genotyped using TaqMan nuclease assay
(Applied Biosystems, Warrington, U.K.) according to the manu-
facturer’s protocol. Genotyping was performed blind to case-
control status and double scored to minimize error. Primers and
probes were as follows: forward primer GCAGTTTAGGGTC-
TAATGAGGTAAGTG, reverse primer CCCTGGGTATC-
TAGGTACCTTATCA, FAM probe CAGCATCCAATA-
GAAGT, VIC probe CAGCATCCAACAGAAGT.
Quality controls
Agilent metrics. An initial set of Agilent quality metrics for
red and green raw intensity probe signals was used to flag
problematic samples. Signal intensity, background noise, signal to
noise ratio and derivative log ratio spread (DLRS, which measures
the spread of log ratio difference between consecutive probes)
summarised data quality across all probes and provided us with an
initial quality assessment independent from subsequent processing
step. Metrics were ranked as ‘Excellent’, ‘Good’ or ‘Poor’ based on
the thresholds proposed by OGT. Samples with at least one metric
flagged as ‘Poor’ were excluded from further analysis.
Sample correlation. To identify potential sample swaps, we
computed Pearson’s correlation coefficient between pairs of
samples using n= 452 clusterable CNVs. Based on the overall
distribution of correlation coefficients (Figure S8) we selected a
cut-off of 0.7 to flag pairs of samples as correlated. Samples
showing correlation greater than this cut-off were flagged as
problematic.
Consistency of familial relationships. To identify incon-
sistent maternal and paternal relationships, we used a likelihood-
based approach. We fitted a model H0 of true paternity (resp.
maternity) and a model of non-paternity H1 (resp. maternity) to
the genotype data from N=318 clustered CNVs with MAF .0.3.
We used a Bayes factors threshold of 100 in favor of non-paternity
to flag likely problematic parent-offspring relationships.
Heterozygosity. We used genome-wide sample heterozygos-
ity as a criteria to exclude samples from the analysis. We computed
the heterozygosity based on a set of 310 autosomal clusterable
CNVs with high confidence genotype calls (posterior probability.
95% based on CNVtools output). We plotted the average number
of heterozygous against the genotype call rate. Samples with
heterozygosity z-score ,25 and call rate ,98% or heterozygosity
z-score .2 and call rate ,92% were flagged as outliers for the
analysis (Figure S9).
Gender check. We used a set of 10 regions without
annotated CNVs on chromosome X to determine the number of
copies of chromosome X and therefore infer gender. This QC step
together with sample tracking led to the identification of a full
plate swap between plate 116 and 118 which could be recovered.
Sample tracking. Sample tracking was performed on a set of
40 CNVs genotyped by either the WTCCC+ or the 1000
Genomes project with CEUMAF.10% that are well-tagged (r2.
0.9) by SNPs present on the ImmunoChip (Figure S10). A
threshold of 80% concordance was used to flag outliers.
QC strategy
A merged list of flagged samples was generated, and whenever
possible manual inspection was used to resolve problematic
samples. Any sample that failed at least one of these quality tests
and that could not be resolved was discarded from the analysis.
We also checked that plate rows and columns showed comparable
CNV intensity data and did not find any systematic change (Figure
S11).
Association testing method
Association tests use the FBAT strategy [21,22] implemented in
the version 2.0 of the CNVtools [19] package. For chromosome X
CNVs not located in the pseudo-autosomal region, we only
compared the CNV intensity between daughters and mothers
(hence restricting the data to approximately half of the sample
size).
Supporting Information
Figure S1 Heritability as a pipeline selection strategy. A measure
of heritability is used to select the optimal pipeline for each CNV
locus. Each boxplot quantifies heritability for a given pipeline
(from N1 standing for normalised1 to N6 standing for normal-
ised6, see Methods for a description of these normalization
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choices). Boxplots are ordered according to increasing heritability.
Pipelines whose data is rescaled according to its first principal
component are marked in blue, whereas pipelines whose data is
rescaled according to heritability probe scaling are marked in dark
green. The magenta horizontal line represents the average
heritability measured across all pipelines. The optimal pipeline
selects the most heritable pipeline at every CNV locus. The
rationale for this choice is that probes with heritable signals are
more likely to capture true heritable CNV differences, and less
likely to be affected by noise.
(EPS)
Figure S2 Comparison of association P-values using FBAT-
CNV and discrete genotyping calls for T1D associated CNVs
located in the MHC complex. In order to empirically assess the
power of family based association tests a subset of clusterable
CNVs known to be positively associated with T1D was used to
compare intensity-based FBAT-CNV P-values with genotype-
based TDT P-values. A - Comparison of association P-values using
FBAT-CNV (x-axis) and TDT (y-axis) for N=22 T1D associated
CNVs located in the MHC complex. B - Zoom in on the left-
bottom corner of Figure S2A.
(EPS)
Figure S3 Family and case control (WTCCC+) replication data
for CNVR341.1 and for its best clusterable tagging CNV
CNVR334.3. A - Top association in the T1D familial cohort for
unclusterable CNVR341.1 (FBAT-CNV P-value = 3.39 1026). B -
Intensity data for CNVR341.1 in the WTCCC+ case control data
(unclusterable, hence no association P-value available). C -
Intensity data for the clusterable CNVR334.3 (FBAT-CNV
P=5.8 1024) in the same 1q21 region in the T1D familial cohort.
D - Intensity data for the correlated CNVR334.3 (CNVtools case-
control P = 0.24) in the WTCCC+ case control dataset.
(EPS)
Figure S4 Primary and conditional on rs689 FBAT-CNV test of
association for INS VNTR. A - First principal component PC1
intensity data for INS VNTR (FBAT-CNV P-value = 10242. B -
Third principal component PC3 intensity data for INS VNTR
after excluding families where either of the parents is heterozygous
at SNP rs689 (FBAT-CNV P-value = 0.82).
(EPS)
Figure S5 Mixed probe design with breakpoint and internal
sequence probes. One of the innovations of the CGH array is the
introduction of a mixed probe design consisting of both quantitative
internal sequence probes and qualitative breakpoint probes for loci
with known breakpoints, as opposed to standard CGH probe design
where all probes are internal to the CNV locus.
(EPS)
Figure S6 Design of probes over CNV breakpoints. Each locus
with known breakpoint is targeted by three qualitative probes: one
probe spanning the breakpoint junction on the alternate non-
reference allele (ALT) and two probes spanning each one of the
breakpoints on the reference allele (REF). To maximize discrim-
ination between the three sequence probes, these probes are
designed to be centered on different locations that depend on
whether the targeting breakpoint is classified as blunt, micro-
homology (mH) or non-templated sequence (NTS). If the break-
point is blunt the ALT probe is centered on the breakpoint,
whereas the left-hand reference probe and the right-hand
reference probe are respectively centered on the start and on
the end of the breakpoint on the REF sequence. If the breakpoint
is a micro-homology, the ALT probe is centered on the
micro-homology, the left hand-side REF probe is centered on
the end of the micro-homology and the right hand-side REF probe
is centered at the end of the breakpoint. If the breakpoint is
categorized as non-template sequence, the ALT probe is centered
on the midpoint of the non-templated sequence, whereas the left-
hand REF probe and the right-hand REF probe are respectively
centered on the start and on the end of the breakpoint on the
reference sequence.
(EPS)
Figure S7 Breakpoint probe design examples. Examples of
reference (red) and alternate (green) alleles and breakpoint probe
positioning for respectively blunt, micro-homology and non-
templated sequence deletions. Start and end refer to start and
end of breakpoint detected in reference allele. In case of blunt
deletions the left-hand (right-hand) side reference probe will bind
to the start (end) of the deletion on the reference allele, and the
alternate probe will bind to the deletion breakpoint on the
alternate allele. In case of micro-homology deletions, under the
design assumption that the second micro-homology is being
deleted, the left-hand side reference probe will bind to the end of
the first micro-homology on the reference allele, the right-hand
side reference probe will bind to the end of the deletion on the
reference allele and the alternate reference probe will bind to the
middle of the micro-homology on the alternate allele to maximize
discrimination between breakpoint probe sequences. In case of
non-template sequence deletions, where a sequence is inserted at
the breakpoint, the left-hand (right-hand) side reference probe will
bind to the start (end) of the deletion on the reference allele, and
the alternate probe will bind to the middle of the non-template
sequence on the alternate allele to maximize discrimination
between probe sequences.
(EPS)
Figure S8 Distribution of R2 correlation between pairs of
unrelated individuals. Squared Pearson correlation coefficient
(R2.0) is measured between pairs of unrelated samples across 452
clusterable CNVs. A cutoff of R2= 0.7 is used to flag highly
correlated samples likely to result from technical artifacts (such as
aliquoting issues).
(EPS)
Figure S9 Genotype call rate versus heterozygosity. Heterozy-
gosity z-score (x-axis) is plotted against genotype call rate (y-axis)
based on a set of 310 autosomal clusterable CNVs with high
confidence genotype calls (95% posterior probability based on
CNVtools output). Each point is a sample. Red samples (z-score
,25 and genotype call rate ,98% or z-score .2 and genotype
call rate ,92%) are flagged as problematic.
(EPS)
Figure S10 Genotype concordance between CNV genotypes
and ImmunoChip genotypes. A set of 40 CNVs genotyped by
either the WTCCC+ or the 1000 Genomes project with CEU
MAF.10% that are well-tagged (R2.0.9) by SNPs present on the
ImmunoChip is used for sample tracking. Each datapoint in the
plots is a sample. The x-axis represents plate position and the y-
axis represents genotype concordance between genotypes based on
CNVtools posterior probabilities and ImmunoChip genotypes.
The scatterplot on the left-hand side (A) show the distribution of
genotype concordance under the null hypothesis of no concor-
dance with ImmunoChip genotypes. The right-hand side
scatterplot (B) shows the estimated genotype concordance with
ImmunoChip genotypes. A threshold of 80% concordance is used
to flag outliers. The long vertical line at the bottom of the right-
hand side plot flags two full plate swaps.
(EPS)
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Figure S11 Distribution of raw un-normalized red intensity signal
across plates for samples passing quality controls. Plate rows and
columns show comparable CNV intensity data before data pre-
processing and normalization. A - Boxplots of raw red intensity
signal across CGH array plate rows E,F,G and H. B - Boxplots of
raw red intensity signal across CGH array plate columns 1 to 12.
(EPS)
Table S1 Source of CNVs targeted by the aCGH, before and
after applying QC filters.
(CSV)
Table S2 Type of CNVs targeted by the aCGH, before and
after applying QC filters.
(CSV)
Table S3 Targeted CNVs with associated FBAT P-values.
(CSV)
Table S4 BED file for T1D CNV array design.
(TXT)
Text S1 Description of array and probe design.
(DOCX)
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